
|Articles|July 1, 2002
Anti-VEGF therapy holds promise for CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Midyear cataract check-in: What 2026 has brought to the OR and beyond
3
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5





















